Logo image of PAVM

PAVMED INC (PAVM) Stock Fundamental Analysis

NASDAQ:PAVM - Nasdaq - US70387R4039 - Common Stock - Currency: USD

0.7918  +0.01 (+1.51%)

Fundamental Rating

2

Overall PAVM gets a fundamental rating of 2 out of 10. We evaluated PAVM against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PAVM have multiple concerns. PAVM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PAVM has reported negative net income.
PAVM had a negative operating cash flow in the past year.
In the past 5 years PAVM always reported negative net income.
In the past 5 years PAVM always reported negative operating cash flow.
PAVM Yearly Net Income VS EBIT VS OCF VS FCFPAVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of 48.17%, PAVM belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 48.17%
ROE N/A
ROIC N/A
ROA(3y)-141.22%
ROA(5y)-165.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PAVM Yearly ROA, ROE, ROICPAVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

With an excellent Profit Margin value of 364.77%, PAVM belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for PAVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 364.77%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PAVM Yearly Profit, Operating, Gross MarginsPAVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

PAVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PAVM has been reduced compared to 1 year ago.
PAVM has less shares outstanding than it did 5 years ago.
PAVM has a worse debt/assets ratio than last year.
PAVM Yearly Shares OutstandingPAVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
PAVM Yearly Total Debt VS Total AssetsPAVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

PAVM has an Altman-Z score of -18.87. This is a bad value and indicates that PAVM is not financially healthy and even has some risk of bankruptcy.
PAVM's Altman-Z score of -18.87 is on the low side compared to the rest of the industry. PAVM is outperformed by 86.70% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.87
ROIC/WACCN/A
WACC6.14%
PAVM Yearly LT Debt VS Equity VS FCFPAVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 0.06 indicates that PAVM may have some problems paying its short term obligations.
PAVM's Current ratio of 0.06 is on the low side compared to the rest of the industry. PAVM is outperformed by 97.34% of its industry peers.
A Quick Ratio of 0.06 indicates that PAVM may have some problems paying its short term obligations.
The Quick ratio of PAVM (0.06) is worse than 97.34% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
PAVM Yearly Current Assets VS Current LiabilitesPAVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

PAVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.30%, which is quite impressive.
The Revenue has grown by 165.39% in the past year. This is a very strong growth!
EPS 1Y (TTM)61.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)165.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%25.92%

3.2 Future

The Earnings Per Share is expected to grow by 24.80% on average over the next years. This is a very strong growth
PAVM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 149.88% yearly.
EPS Next Y34.52%
EPS Next 2Y35.57%
EPS Next 3Y24.8%
EPS Next 5YN/A
Revenue Next Year50.08%
Revenue Next 2Y128.81%
Revenue Next 3Y175.66%
Revenue Next 5Y149.88%

3.3 Evolution

PAVM Yearly Revenue VS EstimatesPAVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
PAVM Yearly EPS VS EstimatesPAVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PAVM. In the last year negative earnings were reported.
Also next year PAVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PAVM Price Earnings VS Forward Price EarningsPAVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PAVM Per share dataPAVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PAVM's earnings are expected to grow with 24.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.57%
EPS Next 3Y24.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PAVM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAVMED INC

NASDAQ:PAVM (2/21/2025, 8:00:02 PM)

0.7918

+0.01 (+1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners12.85%
Inst Owner Change-7.23%
Ins Owners9.42%
Ins Owner Change0%
Market Cap8.77M
Analysts80
Price Target9.18 (1059.38%)
Short Float %3.64%
Short Ratio1.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.4%
Min EPS beat(2)-28.52%
Max EPS beat(2)19.72%
EPS beat(4)2
Avg EPS beat(4)-14.05%
Min EPS beat(4)-53.5%
Max EPS beat(4)19.72%
EPS beat(8)5
Avg EPS beat(8)-2.79%
EPS beat(12)5
Avg EPS beat(12)-7.04%
EPS beat(16)5
Avg EPS beat(16)-11.98%
Revenue beat(2)0
Avg Revenue beat(2)-15.47%
Min Revenue beat(2)-20.28%
Max Revenue beat(2)-10.67%
Revenue beat(4)0
Avg Revenue beat(4)-9.69%
Min Revenue beat(4)-20.28%
Max Revenue beat(4)-1.87%
Revenue beat(8)2
Avg Revenue beat(8)-17.67%
Revenue beat(12)2
Avg Revenue beat(12)-33.14%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)55.12%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-40.82%
Revenue NQ rev (3m)-71.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.18
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-4.13
FCFYN/A
OCF(TTM)-4.11
OCFYN/A
SpS0.36
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 48.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 364.77%
GM N/A
FCFM N/A
ROA(3y)-141.22%
ROA(5y)-165.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.59%
Cap/Sales 5.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -18.87
F-Score5
WACC6.14%
ROIC/WACCN/A
Cap/Depr(3y)236.66%
Cap/Depr(5y)262%
Cap/Sales(3y)236.38%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y34.52%
EPS Next 2Y35.57%
EPS Next 3Y24.8%
EPS Next 5YN/A
Revenue 1Y (TTM)165.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%25.92%
Revenue Next Year50.08%
Revenue Next 2Y128.81%
Revenue Next 3Y175.66%
Revenue Next 5Y149.88%
EBIT growth 1Y27.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year154.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.83%
OCF growth 3YN/A
OCF growth 5YN/A